Stereotactic radiotherapy(SRT) combined with transcatheter arterial chemoembolization(TACE) for hepatocellular carcinoma: Phase II trial

UMIN ID: UMIN000000640

Registered date:01/04/2007

Basic Information

• Recruitment status: Complete: follow-up complete
• Health condition(s) or Problem(s) studied: hepatocellular carcinoma
• Date of first enrollment: 2007/04/01
• Target sample size: 100
• Countries of recruitment: Japan
• Study type: Interventional
• Intervention(s): Stereotactic radiotherapy

Outcome(s)

• Primary Outcome: Three year local pogression free survival
• Secondary Outcome: Three year overall survival Median overall survival Median overall progression free survival Median local progression free survival Median event free survival Type of progression Acute complication rate Chronic complication rate Severe complication rate

Key inclusion & exclusion criteria

• Age minimum: 20years-old
• Age maximum: Not applicable
• Gender: Male and Female
• Exclude criteria: 1.Active infectious disease needing treatment except for external application. 2.In or suspected pregnancy or breast-feeding 3.mental disease which prohibit the patients from understanding this trial. 4.successive steroid use ( oral or intra-venous administration).

Related Information

• Primary Sponsor: Liver radiothrapy group
• Source(s) of Monetary Support: Liver radiothrapy group